MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer
Journal of Clinical Investigation · 16.12.2024 · 134 (24)
DOI: 10.1172/jci182217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 22.10.2024. Verfasst von Jiawei Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm, Cetuximab. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BRAF V600E -mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis. The combination of anti-BRAF/anti-EGFR (encorafenib/cetuximab) treatment for patients with BRAF V600E -mutant mCRC improves clinical benefits; unfortunately, inevitable acquired resistance limits the treatment outcome, and the mechanism has not been validated. Here, we discovered that monoacylglycerol O-acyltransferase 3–mediated (MOGAT3-mediated) diacylglycerol (DAG) accumulation contributed to acquired resistance to encorafenib/cetuximab by dissecting a BRAF V600E -mutant mCRC patient–derived xenograft (PDX) model exposed to encorafenib/cetuximab administration. Mechanistically, the upregulated MOGAT3 promoted DAG synthesis and reduced fatty acid oxidation–promoting DAG accumulation and activated PKCα/CRAF/MEK/ERK signaling, driving acquired resistance. Resistance-induced hypoxia promoted MOGAT3 transcriptional elevation; simultaneously, MOGAT3-mediated DAG accumulation increased HIF1A expression at the translation level through PKCα/CRAF/eIF4E activation, strengthening the resistance status. Intriguingly, reducing intratumoral DAG with fenofibrate or PF-06471553 restored the antitumor efficacy of encorafenib/cetuximab in resistant BRAF V600E -mutant mCRC, which interrupted PKCα/CRAF/MEK/ERK signaling. These findings reveal the critical role of the metabolite DAG as a modulator of encorafenib/cetuximab efficacy in BRAF V600E -mutant mCRC, suggesting that fenofibrate might prove beneficial for resistant BRAF V600E -mutant mCRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Key Laboratory of Biological Treatment of Zhejiang Province, Hangzhou, China.
- Key Laboratory of Integrated Traditional Chinese and Western Medicine Research on Anorectal Diseases of Zhejiang Province, Hangzhou, China.
- School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
- Key Laboratory of Regenerative Medicine of Ministry of Education, Institute of Aging and Regenerative Medicine, Jinan University, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Wang, H., Zhou, W., Luo, X., Wang, H., Meng, Q., Chen, J., Chen, X., Liu, Y., Chan, D. W., Ju, Z., & Song, Z. (2024). MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer. Journal of Clinical Investigation, 134(24). https://doi.org/10.1172/jci182217
Vancouver
Wang J, Wang H, Zhou W, Luo X, Wang H, Meng Q, et al. MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer. Journal of Clinical Investigation. 2024;134(24). doi:10.1172/jci182217
BibTeX
@article{Wang2024,
author = {Wang, Jiawei and Wang, Huogang and Zhou, Wei and Luo, Xin and Wang, Huijuan and Meng, Qing and Chen, Jiaxin and Chen, Xiaoyu and Liu, Yingqiang and Chan, David W and Ju, Zhenyu and Song, Zhangfa},
title = {MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {24},
doi = {10.1172/jci182217}
}
EUVIMED